Media stories about Vanda Pharmaceuticals (NASDAQ:VNDA) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a news impact score of 0.24 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.975036451756 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
Vanda Pharmaceuticals (VNDA) opened at $14.20 on Wednesday. Vanda Pharmaceuticals has a 1 year low of $11.90 and a 1 year high of $18.99. The company has a market cap of $637.97, a PE ratio of -44.38 and a beta of 1.29.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The company had revenue of $41.30 million for the quarter, compared to analysts’ expectations of $43.90 million. During the same quarter in the prior year, the company posted ($0.01) earnings per share. Vanda Pharmaceuticals’s revenue for the quarter was up 7.3% compared to the same quarter last year. research analysts predict that Vanda Pharmaceuticals will post -0.44 earnings per share for the current fiscal year.
Several research analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 19th. Oppenheimer set a $26.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, October 29th. BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. ValuEngine cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Finally, Piper Jaffray Companies set a $26.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, October 19th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Vanda Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $21.50.
In other Vanda Pharmaceuticals news, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $15.30, for a total transaction of $2,933,928.00. Following the sale, the insider now directly owns 1,031,848 shares in the company, valued at $15,787,274.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James Patrick Kelly sold 9,155 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.35, for a total transaction of $140,529.25. Following the sale, the chief financial officer now owns 144,721 shares in the company, valued at $2,221,467.35. The disclosure for this sale can be found here. Insiders sold 209,483 shares of company stock worth $3,205,205 in the last ninety days. 7.60% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Vanda Pharmaceuticals (VNDA) Earning Somewhat Favorable Press Coverage, Study Finds” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/17/vanda-pharmaceuticals-vnda-earning-somewhat-favorable-press-coverage-study-finds.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.